Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107413 | 0.73 | MC4R (0.37) | KCNH2MEN1KMT2A | |
| SCHEMBL29900980 | 0.73 | LMNA (0.51) | KCNH2LMNAL3MBTL1P2RX7MEN1 | |
| SCHEMBL12653659 | 0.72 | LMNA (0.45) | KCNH2LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL12942082 | 0.72 | CD44 (0.56) | CD44PNMTMAOB | |
| SCHEMBL14012985 | 0.69 | CD44 (0.53) | CD44PNMTMAOB | |
| SCHEMBL14355970 | 0.69 | HTR1A (0.49) | — | |
| SCHEMBL330124 | 0.69 | CD44 (0.56) | CD44PNMTMAOB | |
| SCHEMBL30613500 | 0.69 | ADRA2C (0.58) | LMNAL3MBTL1P2RX7MEN1KMT2A | |
| SCHEMBL5776703 | 0.69 | P2RX3 (0.46) | — | |
| SCHEMBL21744609 | 0.69 | CYP2A13 (0.48) | CD44MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1483257-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003076427-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | CD44 4761/4885KCNH2 424/4885LMNA 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.